Clinical Trial Search

Primary: Maximum Observed Plasma Concentration (Cmax) of Entrectinib — 296.140; 213.570; 183.680; 235.990 nmol/L

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by Protocol Definition of AE — 24; 44 Participants

Primary: Rate of Adverse Events — 0; 0; 5 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events — 3; 0; 0; 4 Participants

Primary: Number of Participants With Adverse Events (Aes) and Adverse Drug Reactions (ADRs) — 0; 2; 3; 0 Participants

Primary: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Rosuvastatin, Sildenafil and Furosemide. — 161; 165; 532; 482 ng*h/mL

Primary: Number of Participants With At Least One Treatment-emergent Adverse Event (TEAEs) — 6; 3; 4; 3 Participants

Primary: Number of Patients Who Developed Does-limiting Toxicity (DLT) — 0; 2; 0; 0 Participants

Primary: Change From Baseline in Adjusted Mean (AM) Percentage (%) of CMAP Total Amplitude at Week 28 — 73.62; 74.78; 84.23 % of AM of CMAP total amplitude — p=0.8769

Primary: Phase 1a: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 1; 0 participants

Primary: Total Recovery of Radioactivity in Urine as Percentage of Total Radioactive Dose of PF-06865571 Administered — 48.9; 51.5 Percentage of Dose

Primary: Maximal Knee Extensor Velocity — 10.83; 11.91; 11.24 rad/s — p=0.0833

Primary: Number of Patients Who Developed Does-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: Absence of Dose Limiting Toxicity — 3; 1; 3; 9 Participants

Primary: Maximum Plasma Concentration (Cmax) of Rosuvastatin — 2.178; 2.625 nanogram per milliliter (ng/mL)